Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04810390
Other study ID # BOFT-0520/PED
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 26, 2021
Est. completion date November 30, 2022

Study information

Verified date July 2022
Source Faes Farma, S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of seasonal allergic conjunctivitis (SAC) or perennial allergic conjunctivitis (PAC).


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date November 30, 2022
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 2 Years to 18 Years
Eligibility Inclusion Criteria: - 1. Male or female patients from 2 to under 18 years of age at V1a. - 2. Documented history of AC before V1a. - 3. Documented positive skin prick test and/or positive validated IgE test to seasonal (e.g. grass, ragweed, and/ or tree pollen) and/or perennial allergen (e.g. cat dander, dog dander, dust mites and/ or cockroach) within 6 months before V1a or a positive skin prick test at V1a. - 4. Signs and symptoms of AC, i.e. tearing, itching and redness, that are likely to continue for the next weeks. Minimum score of four (in at least one eye) on an 11-item numeric rating scale in at least one of three categories at V1a. - 5. Understanding of functioning and willingness to use e-diary at V1b and throughout study duration. - 6. Willing to comply in all aspects of the study, including: 1. use of IMP from V1b to V5a 2. attending scheduled visits and completing telephone interviews. - 7. Signed age-appropriate assent form (in participants 12 years of age and older) and written informed consent by the LAR in all cases. If a patient turns 18 years old during the clinical trial, a new written informed consent form will be provided and signed by the patient if he/she is willing to continue participating in the study. - 8. Be able to self-administer eye drops satisfactorily or have a caregiver or LAR routinely available for this purpose. If a caregiver or LAR will be in charge of administering eye drops then he/she must attend Visit 1b, in order to be trained for administration of eye drops on-site. - 9. For females of childbearing potential only: willingness to perform pregnancy tests, acceptance to use highly effective methods of birth control throughout the study duration. Highly effective methods of birth control include: combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomised partner (provided that partner is the sole sexual partner of the clinical trial participant and has documentation of azoospermia) or sexual abstinence (if defined as refraining from heterosexual intercourse during the entire period of risk associated with the clinical trial treatment). The investigator is responsible for determining whether the subject has adequate birth control for study participation. Exclusion Criteria: - 1. History of known contraindications or sensitivities to the use of the IMPs or any of their components. - 2. History of intraocular surgery within the previous 2 years before V1a, or planned surgery during study participation and within 2 weeks after follow-up. - 3. History of ocular trauma (within the previous 6 months before V1a). - 4. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease within the previous year before V1a. - 5. History of any clinically significant external ocular disease within 30 days before V1a. - 6. Presence of dry eye, active blepharitis, active Meibomian gland dysfunction, active rosacea affecting the ocular surface/ lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect study outcome at V1a. - 7. Known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye). - 8. History of treatment failure to topical antihistamines. - 9. Prior (within 2 years before V1a), current or anticipated anti-allergy immunotherapy. - 10. Prior (within 4 weeks before V1a), current or anticipated corticosteroid treatment (systemic or local, in case of depot-corticosteroids: within 6 weeks before V1a). - 11. Prior (within 1 week before V1a), current or anticipated use of any ophthalmic agents (including artificial tears), except IMPs (starting at V1b). - 12. Wearing of contact lenses 24 hours before ophthalmologic tests (V1a) and during clinical trial participation until V6. - 13. Prior (within 2 weeks before V1a), current or anticipated systemic or intranasal treatment for allergic rhinitis. - 14. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities. - 15. Pregnant woman, breastfeeding woman or woman planning a pregnancy. - 16. Body weight below the 5th percentile for their age (patients 10 years of age or younger only). - 17. Patient has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before V1a or is currently enrolled in an investigational interventional study. - 18. Any condition that, in the opinion of the investigator, may jeopardise the clinical trial conduct according to the protocol. (For example, evidence of diseases, medications or laboratory abnormalities that could alter the conduct of the study).

Study Design


Intervention

Drug:
Bilastine
Ophthalmic solution 0.6%
Placebo
Ophthalmic solution

Locations

Country Name City State
Spain Instituto Oftálmologico Quironsalud A Coruña A Coruña
Spain Hospital Universitari German Trias i Pujol (HGTiP), Badalona
Spain Hospital Universitario de Cruces Barakaldo Bizkaia
Spain Hospital Universitari Dexeus Barcelona
Spain Hospital Universitari Vall D'Hebron Barcelona
Spain Hospital General La Mancha Centro Ciudad Real
Spain Clínica Universidad de Navarra (CUN)- Sede Madrid Madrid
Spain Hospital Universitario Quirónsalud Madrid Madrid
Spain Hospital Quirónsalud Málaga Málaga
Spain Hospital Quirónsalud Marbella Marbella
Spain Hospital Universitario Central de Asturias Oviedo
Spain Clínica Juaneda Palma De Mallorca
Spain Clínica Universidad de Navarra Pamplona
Spain Hospital Universitario Donostia San Sebastián
Spain Hospital de Dia Quirónsalud Ave María Sevilla
Spain Hospital Quirón Valencia Valencia
Spain Hospital Universitario Dr. Peset Aleixandre Valencia
Spain Hospital Universitario Araba Vitoria

Sponsors (2)

Lead Sponsor Collaborator
Faes Farma, S.A. Dynamic Science S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs) It will be reported the incidence of related ocular treatment-emergent adverse events (ocular r-TEAEs) as primary safety endpoint. 8 weeks
Secondary Incidence of treatment-emergent adverse events (TEAEs) It will be reported the incidence of treatment-emergent adverse events (TEAEs) 8 weeks
Secondary Incidence of ocular treatment-emergent adverse events (ocular TEAEs) It will be reported the incidence of ocular treatment-emergent adverse events (ocular TEAEs) 8 weeks
Secondary Incidence of related treatment-emergent adverse events (r-TEAEs) It will be reported the incidence of related treatment-emergent adverse events (r-TEAEs) 8 weeks
Secondary Incidence of abnormal clinical findings from ophthalmic examinations after instillation of IMP It will be reported the incidence of abnormal clinical findings from ophthalmic examinations after instillation of IMP.
Ophthalmic examination will consist of:
Best-corrected visual acuity test with age-appropriate techniques
Slit lamp biomicroscopy
Intraocular pressure in children who can cooperate with the test and do not require general anaesthesia
Non-dilated fundus examination
8 weeks
Secondary Mean peak ocular discomfort score after on-site instillation of IMP Potential peak ocular discomfort caused by IMPs will be evaluated separately for each eye by the patient, with the aid of LAR if required, immediately upon instillation, on an 11-item numeric rating scale (from 0 to 10), which will include age-appropriate visual scales for children. 8 weeks
Secondary Mean ocular burning, stinging, tearing, blurring and stickiness scores after on-site instillation of IMP Ocular tolerability (burning, stinging, tearing, blurring, and stickiness) of IMPs will be assessed separately for each eye by the patient with the aid of LAR if required,on an 11-item numeric rating scale (from 0 to 10), which will include age-appropriate visual scales for children. 8 weeks
Secondary Absolute value as well as absolute and relative changes from baseline of average daily total eye symptoms score (TESS) over the entire 8-week treatment period The total eye symptoms score (TESS) based on the patient's e-diary is defined as the sum of the ocular itching, redness, and tearing scores. For each patient the worst daily sum of ratings will be selected for analysis. Additional exploratory analyses will be performed for each ocular symptom using the mean results of both eyes. 8 weeks
Secondary Absolute value as well as absolute and relative changes from baseline of average daily TESS at each week of the 8-week treatment period The total eye symptoms score (TESS) based on the patient's e-diary is defined as the sum of the ocular itching, redness, and tearing scores. For each patient the worst daily sum of ratings will be selected for analysis. Additional exploratory analyses will be performed for each ocular symptom using the mean results of both eyes. 8 weeks
Secondary Absolute value as well as absolute and relative changes from baseline of average daily itching, redness and tearing scores over the entire 8-week treatment period The average value for both eyes in each single symptom score will be used. 8 weeks
Secondary Absolute value as well as absolute and relative changes from baseline of average daily itching, redness and tearing scores at each week of the 8-week treatment period The average value for both eyes in each single symptom score will be used. 8 weeks
Secondary For seasonal allergic conjunctivitis (SAC) patients only, the average daily TESS over the 2-week period of peak total eye symptoms score For SAC patients, the average daily TESS and single symptom scores over the 2-week period of peak TESS and the 2-week period of peak single symptom scores, respectively, will be analysed using ANOVA. 8 weeks
Secondary For seasonal allergic conjunctivitis (SAC) patients only, the average daily itching, redness and tearing scores over the 2-week period of peak symptoms score For SAC patients,the average daily itching, redness and tearing scores over the 2-week period of peak symptoms scores, respectively, will be analysed using ANOVA. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03660878 - A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Phase 1/Phase 2
Completed NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Phase 2
Completed NCT01697969 - Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Phase 4
Completed NCT01685242 - A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle Phase 3
Completed NCT01439815 - An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Phase 4
Completed NCT01294969 - Patient Perception Study for AL-4943A Phase 4
Completed NCT01471184 - The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo Phase 1
Completed NCT00609128 - Effect of Olopatadine on Allergic Tear Mediators N/A
Recruiting NCT05969236 - A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults Phase 1
Active, not recruiting NCT04619017 - Airway Immune Response to Allergens (Use Lay Language Here) Phase 1
Not yet recruiting NCT01012752 - A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts Phase 3
Completed NCT01698814 - A Six-Week Safety Study of an Investigational Ophthalmic Solution Phase 3
Completed NCT01754766 - AGN-229666 for the Treatment of Allergic Conjunctivitis Phase 2
Completed NCT01443442 - Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Phase 4
Completed NCT01203540 - Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Phase 4
Completed NCT00987272 - Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects Phase 3
Completed NCT00769886 - Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis. Phase 3
Completed NCT00534794 - Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Phase 4
Completed NCT00586664 - Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis Phase 3
Completed NCT00569777 - Safety Study of a Contact Lens With Ketotifen in Healthy, Normal Volunteers Phase 3